About IntelGenx

IntelGenx is a leading drug delivery company providing single-site, end-to-end contract development and manufacturing services of novel oral thin film and transdermal drug products for the pharmaceutical and animal health markets, spanning the entire drug development and commercial product cycle.

IntelGenx’s superior film technologies, including VersaFilm®, VetaFilm™ and VevaDerm™, allow for next generation pharmaceutical products that address unmet medical needs and bring tangible benefits for patients and commercial advantages to our partners.

Facts and figures

  • Sponsored 38 clinical studies, 7 pivotal studies and one phase 2 clinical trial.
  • Our employees have nearly 90 years of combined formulation experience
  • Our employees have more than 50 years of combined analytical experience
  • We have screened more than 100 small molecules for film applicability


Dr Horst Zerbe Aug 8 2016 Web LAS8124 00000002

Horst G. Zerbe, Ph.D., Dr. Zerbe is the founder of IntelGenx Corp. and was the Chief Executive Officer and Chairman of IntelGenx Technologies Corp. until his retirement in April 2023. In addition, Dr. Zerbe had served as the Chief Executive Officer and Director of IntelGenx Corp., our Canadian Subsidiary, since 2005. He also served as President of both entities until May 2019. Dr. Zerbe retired from his positions as President and Chief Executive Officer on January 1, 2014, and at the request of the Board, was re-appointed as President and CEO effective July 15, 2014.

Dr. Zerbe has more than 35 years of experience in the pharmaceutical industry. He started his career at Schwarz Pharma and subsequently at 3M Pharmaceuticals in Germany. From 1998 to 2005, he served as the President of Smartrix Technologies Inc. in Montreal; prior thereto, from 1994 to 1998, he served as Vice President of R&D and Technology Transfer at LTS Lohmann Therapy Systems in West Caldwell, NJ. During his assignments at 3M and LTS, he gained considerable experience in the technology transfer and commercial manufacturing of transdermal as well as oral film products. Dr. Zerbe has extensive executive level experience, and has been responsible for many strategic and business initiatives. Dr. Zerbe has been involved in new drug development and the acquisition and disposition of new drug candidates and other technology, licensing and distribution matters. He has published numerous scientific papers in recognized journals and holds more than 30 patents.

Our Board believes that both Dr. Zerbe’s length and breadth of industry-specific technical and business experience, and his role as founder and Chief Executive Officer of our subsidiary, IntelGenx Corp., qualifies him to serve on our Board of Directors. Dr. Zerbe was responsible for developing the vision of our company and identifying many of our current partner relationships.

Bernd Melchers Aug 8 2016 LAS8160

Bernd J. Melchers, B.A., Mr. Melchers has been a director of IntelGenx Technologies Corp. since April 2009. From January 2001 until his retirement in December 2004, Mr. Melchers was Managing Director of 3M Dyneon Holding GmbH, Germany and Global Chief Financial Officer of the worldwide operating 3M Dyneon Group, a subsidiary of 3M Corporation headquartered in Minnesota. From July 1995 to December 2000, he served as the Controller at the European Business Center of 3M Medical Markets Europe in Belgium. Prior to this, he held various senior Financial Manager positions at the Medical-Surgical Division of 3M in St. Paul, Minnesota, at 3M Health Care Products, Germany, and at 3M Pharmaceutical Products, Germany.

Our Board believes that Mr. Melchers’ 30 years of experience within the pharmaceutical and health care industry, together with his extensive hands-on international experience in corporate financial management and his extensive operational and financial expertise, as well as his track record and achievements in global financial management positions of pharmaceutical, medical and specialty chemical businesses, qualifies him to serve on our Board of Directors.

Clemens Mayr Aug 8 2016 LAS8181

Clemens Mayr, Mr. Mayr has been a Director of IntelGenx Technologies Corp. since August 2015. Since 2006, he has been a partner of McCarthy Tétrault LLP, a leading Canadian law firm. Prior thereto, Mr. Mayr was partner with Ogilvy Renault LLP from 1999 to 2006 and lawyer at this firm from 1997 to 1999. He practises in the areas of securities and corporate law, particularly in domestic and cross-border mergers and acquisitions, take-over bids and public financings, and has been involved in numerous mergers and acquisitions, as well as venture capital financings. In the course of his practice, he has advised corporations and boards in numerous industries, including in particular life-sciences and technology. He also currently serves as the President and Chief Executive Officer of the Institute of Corporate Directors (Quebec Chapter).

Mr. Mayr received his LLB from the Universite de Montreal in 1990 and was called to the Quebec bar in 1991.

Since February 2017, McCarthy Tetrault LLP has been acting as the Company’s Canadian legal counsel.

Our Board believes that Mr. Mayr’s strong background and experience in corporate governance, M&A and capital markets, as well as his unique qualification to provide guidance to the Company’s executive management to execute its growth strategy, qualifies him to serve on our Board of Directors.

Mark Nawacki Aug 8 2016 LAS8167 2

Mark Nawacki, Mr. Nawacki has been a Director of IntelGenx Technologies Corp. since August 2016. Prior to his appointment, from February to July 2016, Mr. Nawacki was a member of the Scientific Advisory Board of IntelGenx Corp., which provides advice to the Company’s management team. Since February 2015, Mark Nawacki has been the President and CEO of Searchlight Pharma Inc., a Canadian-based private specialty pharmaceutical company focused on the acquisition and commercialization of innovative and unique healthcare and pharmaceutical products. He is also a director of Searchlight Pharma Inc. Fom September 2003 to September 2014, Mr. Nawacki served as Executive Vice President, Business and Corporate Development of Paladin Labs, where he spent more than 11 years building out the company’s commercial and geographic footprint. During his 11-year tenure at Paladin, Mr. Nawacki helped shape the therapeutic focus of Paladin’s Canadian business via licensing and acquisitions, and built Paladin’s international expansion and emerging markets strategy.

Mark holds a BA in International Relations and Russian and East European Studies from the University of Toronto (Trinity), MBA also from the University of Toronto, and is a current member of Chartered Professional Accountants of Ontario (CPA Ontario). He is a past member of the Board of Trustees of the Licensing Executive Society (USA & Canada) and is a former President and Board Member of the Canadian Healthcare Licensing Association.


Monika Trzcinska, Ph.D., Dr. Trzcinska has been a Director of IntelGenx Technologies Corp. since May 2022. Since January 2018, Dr. Trzcinska has been the Partner and co-founder of Bluestar BioAdvisors, LLC, a New York-based boutique, client-centered strategic consulting firm that services companies in the life science industry.

Dr. Trzcinska has more than 20 years of experience in consulting and business development, with broad experience in the life sciences. Prior to her positions with Bluestar BioAdvisors, LLC, from May 2013 to December 2017 she served as a Managing Director and Vice President of Professional Services at Torreya Insights, a life science consulting firm affiliated with Torreya Partners. Prior to these roles she was Director, Business Development at Repligen, Strategic Marketing and Business Development Manager at Sigma-Aldrich and Cyprotex/Apredica, as well as Assistant Editor at Incyte Genomics. Dr. Trzcinska also worked as a researcher and a lecturer at Boston University and Northeastern University in Boston, Massachusetts.

Dr. Trzcinska received her Ph.D. in Experimental Psychology/Neuroscience from University of Ottawa and a B.Sc in Biology and Psychology from Concordia University, Montreal.

Our Board believes that the breadth of Dr. Trzcinska’s life science industry experience, her consulting and business development experience, as well as her scientific expertise qualifies her to serve on our Board of Directors.

Ingrid Zerbe 2 Web Aug 16 2016

Sahil Kirpekar, M.D., Dr. Kirpekar has been a Director of IntelGenx Technologies Corp. since December 2023. He is the Chief Business Officer at atai Life Sciences since 2022. As the CBO at atai Life Sciences, Dr. Kirpekar is responsible for portfolio strategy and capital allocation, internal and external investments as well as early commercial capabilities for atai’s pipeline in neuro-psychiatry. Dr. Kirpekar's tenure at Otsuka Pharmaceutical Co., Ltd., where he last served as the Head of Business Development and Co-chair of the Global Business Development Committee, demonstrated his ability to build a successful pipeline of assets in CNS, Rare disease and Haem-Oncology. He has been the architect of several complex deals, and his leadership and strategic acumen led to the closing of significant transactions valued at over USD 2.7 billion, contributing to the on-going growth and success of the company.

Dr. Kirpekar's diverse experience extends beyond his time at Otsuka. As a strategy consultant at Double Helix Consulting (McCann Health Consulting), he developed and executed commercial and market access strategies for biopharmaceutical companies worldwide.

Dr. Kirpekar became a Director pursuant to the Purchaser Rights Agreement between atai and IntelGenx Technologies Corp., dated March 14, 2021.

Ingrid Zerbe 2 Web Aug 16 2016

Ryan Barrett, Mr. Barrett has been a Director of IntelGenx Technologies Corp. since December 2023. He is the Senior Vice President and General Counsel at atai Life Sciences since August 2020. Mr. Barrett has spent the past decade serving on the executive teams of public and private biotechnology companies, for which he has been responsible for building and leading the legal, corporate development, and intellectual property functions. He has significant experience in strategic transactions as well as public and private financings, including IPOs. Over the course of his career, Mr. Barrett has held multiple strategic and operational roles within various biotechnology, not-for-profit and financial services companies.

Mr. Barrett is an attorney admitted to the bar of the Commonwealth of Massachusetts; he holds a B.S. in biochemistry and a B.A. in Italian language from Trinity College (Hartford, CT), and a J.D. from Case Western Reserve University School of Law (Cleveland, OH). Mr. Barrett has served on multiple boards within the biotechnology and pharmaceutical sector, including presently as Chairman of the Board at GABA Therapeutics and as a Director of Recognify Life Sciences and of Perception Neuroscience.

Mr. Barrett became a Director pursuant to the Purchaser Rights Agreement between atai and IntelGenx Technologies Corp., dated March 14, 2021.

Ingrid Zerbe 2 Web Aug 16 2016

Ingrid Zerbe, Mrs. Zerbe is our Corporate Secretary since 2006. Mrs. Zerbe is the founder of IntelGenx Corp., our Canadian Subsidiary. She served as the President of IntelGenx Corp, from its incorporation in June 2003 until December 2005. She has been a Director of the subsidiary since its incorporation in June 2003 and a Director of the parent company from April 2006 until August 2006. Mrs. Zerbe was the Director, Finance and Administration of IntelGenx Corp. from 2003 to 2016. She holds a bachelor degree in economics from a business school in Bottrop, Germany, and a bachelor degree in social sciences from the University of Dortmund, Germany.